911 related articles for article (PubMed ID: 32755208)
21. Predictors of prostate cancer detection in MRI PI-RADS 3 lesions - Reality of a tertiary center.
Araújo D; Gromicho A; Dias J; Bastos S; Maciel RM; Sabença A; Xambre L
Arch Ital Urol Androl; 2023 Dec; 95(4):11830. PubMed ID: 38117217
[TBL] [Abstract][Full Text] [Related]
22. Analysis of PI-RADS 4 cases: Management recommendations for negatively biopsied patients.
Ullrich T; Arsov C; Quentin M; Laqua N; Klingebiel M; Martin O; Hiester A; Blondin D; Rabenalt R; Albers P; Antoch G; Schimmöller L
Eur J Radiol; 2019 Apr; 113():1-6. PubMed ID: 30927932
[TBL] [Abstract][Full Text] [Related]
23. 3-T Multiparametric MRI Followed by In-Bore MR-Guided Biopsy for Detecting Clinically Significant Prostate Cancer After Prior Negative Transrectal Ultrasound-Guided Biopsy.
Hosseiny M; Shakeri S; Felker ER; Lu D; Sayre J; Ahuja P; Raman SS
AJR Am J Roentgenol; 2020 Sep; 215(3):660-666. PubMed ID: 32755166
[No Abstract] [Full Text] [Related]
24. Validation of the PI-RADS language: predictive values of PI-RADS lexicon descriptors for detection of prostate cancer.
Rudolph MM; Baur ADJ; Haas M; Cash H; Miller K; Mahjoub S; Hartenstein A; Kaufmann D; Rotzinger R; Lee CH; Asbach P; Hamm B; Penzkofer T
Eur Radiol; 2020 Aug; 30(8):4262-4271. PubMed ID: 32219507
[TBL] [Abstract][Full Text] [Related]
25. Value of Dynamic Contrast-Enhanced (DCE) MR Imaging in Peripheral Lesions in PI-RADS-4 Patients.
Ullrich T; Quentin M; Arsov C; Laqua N; Abrar D; Hiester A; Albers P; Antoch G; Schimmöller L
Rofo; 2020 May; 192(5):441-447. PubMed ID: 31622990
[TBL] [Abstract][Full Text] [Related]
26. Second-opinion reads in prostate MRI: added value of subspecialty interpretation and review at multidisciplinary rounds.
Li JL; Phillips D; Towfighi S; Wong A; Harris A; Black PC; Chang SD
Abdom Radiol (NY); 2022 Feb; 47(2):827-837. PubMed ID: 34914006
[TBL] [Abstract][Full Text] [Related]
27. Investigating the role of DCE-MRI, over T2 and DWI, in accurate PI-RADS v2 assessment of clinically significant peripheral zone prostate lesions as defined at radical prostatectomy.
Taghipour M; Ziaei A; Alessandrino F; Hassanzadeh E; Harisinghani M; Vangel M; Tempany CM; Fennessy FM
Abdom Radiol (NY); 2019 Apr; 44(4):1520-1527. PubMed ID: 30361870
[TBL] [Abstract][Full Text] [Related]
28. The Role of PSA Density among PI-RADS v2.1 Categories to Avoid an Unnecessary Transition Zone Biopsy in Patients with PSA 4-20 ng/mL.
Wang ZB; Wei CG; Zhang YY; Pan P; Dai GC; Tu J; Shen JK
Biomed Res Int; 2021; 2021():3995789. PubMed ID: 34671673
[TBL] [Abstract][Full Text] [Related]
29. PI-RADS v2.1 evaluation of prostate "nodule in nodule" variants: clinical, imaging, and pathological features.
Sun M; Xu L; Zhang X; Cao L; Chen W; Liu K; Wu H; Xie D
Insights Imaging; 2024 Mar; 15(1):79. PubMed ID: 38499703
[TBL] [Abstract][Full Text] [Related]
30. Risk-based MRI-directed diagnostic pathway outperforms non-risk-based pathways in suspected prostate cancer biopsy-naïve men: a large cohort validation study.
Bittencourt LK; Guricova K; Zucker I; Durieux JC; Schoots IG
Eur Radiol; 2022 Apr; 32(4):2330-2339. PubMed ID: 35028750
[TBL] [Abstract][Full Text] [Related]
31. Structured approach to resolving discordance between PI-RADS v2.1 score and targeted prostate biopsy results: an opportunity for quality improvement.
Arcot R; Sekar S; Kotamarti S; Krischak M; Michael ZD; Foo WC; Huang J; Polascik TJ; Gupta RT
Abdom Radiol (NY); 2022 Aug; 47(8):2917-2927. PubMed ID: 35674785
[TBL] [Abstract][Full Text] [Related]
32. Comparison of PI-RADS v1 and v2 for multiparametric MRI detection of prostate cancer with whole-mount histological workup as reference standard.
Schaudinn A; Gawlitza J; Mucha S; Linder N; Franz T; Horn LC; Kahn T; Busse H
Eur J Radiol; 2019 Jul; 116():180-185. PubMed ID: 31153562
[TBL] [Abstract][Full Text] [Related]
33. Can the addition of clinical information improve the accuracy of PI-RADS version 2 for the diagnosis of clinically significant prostate cancer in positive MRI?
Polanec SH; Bickel H; Wengert GJ; Arnoldner M; Clauser P; Susani M; Shariat SF; Pinker K; Helbich TH; Baltzer PAT
Clin Radiol; 2020 Feb; 75(2):157.e1-157.e7. PubMed ID: 31690449
[TBL] [Abstract][Full Text] [Related]
34. One-Stop MRI and MRI/transrectal ultrasound fusion-guided biopsy: an expedited pathway for prostate cancer diagnosis.
Tafuri A; Ashrafi AN; Palmer S; Shakir A; Cacciamani GE; Iwata A; Iwata T; Cai J; Sali A; Gupta C; Medina LG; Stern MC; Duddalwar V; Aron M; Gill IS; Abreu A
World J Urol; 2020 Apr; 38(4):949-956. PubMed ID: 31175460
[TBL] [Abstract][Full Text] [Related]
35. Is targeted magnetic resonance imaging/transrectal ultrasound fusion prostate biopsy enough for the detection of prostate cancer in patients with PI-RADS ≥3: Results of a prospective, randomized clinical trial.
Zhang J; Zhu A; Sun D; Guo S; Zhang H; Liu S; Fu Q; Zhang K
J Cancer Res Ther; 2020; 16(7):1698-1702. PubMed ID: 33565519
[TBL] [Abstract][Full Text] [Related]
36. Prospective Evaluation of PI-RADS™ Version 2 Using the International Society of Urological Pathology Prostate Cancer Grade Group System.
Mehralivand S; Bednarova S; Shih JH; Mertan FV; Gaur S; Merino MJ; Wood BJ; Pinto PA; Choyke PL; Turkbey B
J Urol; 2017 Sep; 198(3):583-590. PubMed ID: 28373133
[TBL] [Abstract][Full Text] [Related]
37. Risk-Adapted Strategy Combining Magnetic Resonance Imaging and Prostate-Specific Antigen Density to Individualize Biopsy Decision in Patients With PI-RADS 3 ``Gray Zone'' Lesions.
Akpinar C; Oz DK; Oktar A; Suer E; Ozden E; Haliloglu N; Gulpinar O; Gokce MI; Gogus C; Baltaci S
Clin Genitourin Cancer; 2024 Jun; 22(3):102071. PubMed ID: 38555682
[TBL] [Abstract][Full Text] [Related]
38. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A
Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
[TBL] [Abstract][Full Text] [Related]
39. Which clinical and radiological characteristics can predict clinically significant prostate cancer in PI-RADS 3 lesions? A retrospective study in a high-volume academic center.
Hermie I; Van Besien J; De Visschere P; Lumen N; Decaestecker K
Eur J Radiol; 2019 May; 114():92-98. PubMed ID: 31005183
[TBL] [Abstract][Full Text] [Related]
40. Systematic versus Targeted Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy among Men with Visible Lesions.
Patel HD; Koehne EL; Shea SM; Fang AM; Gorbonos A; Quek ML; Flanigan RC; Goldberg A; Rais-Bahrami S; Gupta GN
J Urol; 2022 Jan; 207(1):108-117. PubMed ID: 34428091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]